Will brepocitinib's non-infectious uveitis Phase 3 topline be positive by 2027-03-31?

Decision tree: P(primary endpoint hit) × P(readout before 2027-03-31). P(hit) ~0.55-0.60 blending JAK orphan autoimmune base rate (~60%) with uveitis-specific difficulty (~50% for novel mechanism). VALOR DM success provides some cross-indication read-through but different disease biology (skin/muscle autoimmune vs ocular inflammation). P(readout within window) ~0.85 given H2 CY2026 guidance plus typical 2-4 month slip buffer through Q1 2027. Joint 0.57 × 0.88 = 0.50.

Two offsetting forces. Pro: brepocitinib has demonstrated Ph3 success in DM establishing the molecule can succeed in a tightly-controlled autoimmune indication; total safety database >1,500 patients reduces tolerability dropout risk. Con: (1) no public NIU Ph2 efficacy data means base rate for JAK-with-Ph2-support (~60%) may not apply; (2) NIU primary endpoints historically difficult (time-to-failure in small trials subject to censoring issues); (3) Roivant has not emphasized NIU in investor messaging as prominently as DM, suggesting internal confidence may be lower. Net 0.48 — slightly below JAK class baseline without confirmed Ph2.

Mix of positive and negative factors yielding near-coin-flip. Positive: brepocitinib safety database mature, severe unmet need in NIU (steroid dependence), VALOR DM success signals molecule efficacy in autoimmune settings. Negative: NIU is a more heterogeneous disease than DM (anterior/intermediate/posterior subtypes with different drug response), primary endpoint variability, no confirmed positive Ph2 NIU data public. Timing window generous. Net 0.52 — slightly above JAK class floor.

NIU Ph3 coin flip with modest context. Base rate 55-65% for JAK-in-autoimmune with Ph2 support; discount to ~50% absent public Ph2 NIU data. VALOR DM success provides marginal cross-indication read-through (different mechanism emphasis: muscle inflammation vs ocular autoimmune). Timing window generous (Q1 2027 buffer). Net 0.50.

Slight positive tilt from three factors: (1) brepocitinib is a dual TYK2/JAK1 inhibitor with broader mechanism than pure JAK1, potentially advantageous in NIU; (2) Pfizer Priovant 25% minority signals PFE commitment to franchise breadth including NIU; (3) VALOR Ph3 hit all 9 secondary endpoints including TIS-related immune markers relevant to uveitis biology. Discount remains for no public Ph2 data and indication difficulty. Net 0.52.

Pure coin flip reflecting insufficient Ph2 NIU data + indication-specific difficulty offsetting VALOR DM success and mature safety database. JAK orphan autoimmune base rate 55-65% anchored to ~50% by NIU-specific endpoint risk and enrollment adequacy unknown. Timing window generous, minimal timing risk.

Coin flip. JAK autoimmune Ph3 base rate 55-65%; uveitis-specific base rate lower (~45-55%). VALOR DM success provides marginal support. Timing window generous. Net 0.50.

Slight negative tilt from no public Ph2 NIU data (applied base rate should be ~55% not 65%) and endpoint complexity. VALOR DM success provides modest counterweight. Net 0.48.

Slight positive tilt from brepocitinib dual mechanism (TYK2/JAK1), mature safety database, and severe unmet need in NIU. Endpoint complexity and no Ph2 data offset. Net 0.52.